The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma

Konstas, A. G. P.; Kozobolis, V P; Tersis, Ioannis; Leech, Jessica N.; Stewart, William C.

doi:10.1038/sj.eye.6700257

Cited by 53 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6][7][8][9][10][11][12] All patients signed an Institutional Review Board approved informed consent form before enrollment. Previously treated patients underwent an untreated washout period comprising 4 weeks for brimonidine, or dorzolamide; 5 weeks for beta-blockers or the dorzolamide/timolol fixed combination; and 6 weeks for prostaglandin analogues.…”

Section: Methodsmentioning

confidence: 99%

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

Konstas

Katsimpris

Kaltsos

et al. 2007

Eye

Self Cite

View full text Add to dashboard Cite

Purpose To evaluate the 24-h intraocular pressure (IOP) control of brimonidine/timolol fixed combination (BTFC) versus the unfixed combination of its individual components, each dosed twice daily, in patients with primary open-angle glaucoma or ocular hypertension. Methods An observer-masked, randomized, crossover, active-controlled, two-centre comparison. Following a 6-week medicine-free period, patients were randomized to BTFC or to the unfixed combination of brimonidine and timolol for 3 months. Patients then were crossed over to the opposite treatment for another 3 months. At the end of the medicinefree period, and each treatment period, patients underwent 24-h IOP measurements at 0600, 1000, 1400, 1800, 2200, and 0200 hours. Results Twenty-eight patients completed this study. Both BTFC and the unfixed components showed a significant IOP reduction from untreated baseline (Po0.0001), and were statistically equal when compared directly, for each individual time point and for the 24-h IOP curve (P40.05). The mean 24-h IOP was 24.671.9 for baseline, 19.271.9 for BTFC, and 19.271.6 mmHg for the unfixed components (P ¼ 1.0). Four patients were discontinued due to side effects. The most common ocular adverse event was ocular hyperaemia (n ¼ 3 with BTFC and n ¼ 5 with the unfixed components, P ¼ 0.7) and systemic adverse events were rare. Conclusion This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24-h IOP reduction from untreated baseline, and statistically equal control when compared directly, at each time point and for the 24-h pressure curve.

show abstract

Section: Methodsmentioning

confidence: 99%

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

Konstas

Katsimpris

Kaltsos

et al. 2007

Eye

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies clearly demonstrated that topical administration of latanoprost 0.005% once daily provided a steady reduction of the IOP during both the day and night in POAG and XFG. [7][8][9][10][11][12][13] To the best of our knowledge, no information is available regarding 24-h curve testing or the mean range of IOP with the newer medication such as travoprost or bimatoprost in patients with exfoliation syndrome (XFS) together with elevated IOP. The purpose of this study was to compare the effects of three PG analogues on the 24-h IOP curve in eyes with XFS and ocular hypertension (OH).…”

Section: Introductionmentioning

confidence: 99%

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Hepşen

Özkaya

2006

Eye

View full text Add to dashboard Cite

“…30,37 Unfortunately, to date there are limited data with respect to the efficacy of this medication in controlling the IOP in XFG. 38 In this current study, we investigated the diurnal IOP reduction at four time points covering a period of 12 daytime hours to help establish the potency of these two medications in XFG. Both treatments significantly reduced the diurnal baseline IOP.…”

Section: Discussionmentioning

confidence: 99%

Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma

Konstas

Mylopoulos

Karabatsas

et al. 2004

Eye

Self Cite

View full text Add to dashboard Cite

Aims To compare the diurnal intraocular pressure (IOP) efficacy and safety of timolol vs latanoprost in subjects with exfoliation glaucoma (XFG). Methods A 3-month prospective, singlemasked, active-controlled, parallel comparison performed in six centres in Greece that randomized subjects in a 1 : 1 ratio to either latanoprost in the evening (2000 hours) and placebo in the morning (0800 hours), or timolol twice daily (0800 and 2000 hours).Results In all, 103 subjects completed the study. After 3 months of chronic dosing, the latanoprost group exhibited a trend to a greater diurnal IOP reduction from an untreated baseline (24.973.2-17.472.9) compared with timolol (24.772.8-18.371.9 mmHg) (P ¼ 0.07). Latanoprost showed a significantly greater IOP reduction at 0800 hours (À8.5 vs À6.0 mm Hg for timolol, Po0.0001) whereas no difference was observed between the two medications at 1000, 1400, and 2000 hours after a Bonferroni Correction. In addition, latanoprost demonstrated a narrower range of diurnal IOP (2.4) than timolol (3.2 mmHg)(P ¼ 0.0017). Safety was similar between groups, except there was more conjunctival hyperaemia with latanoprost (n ¼ 8) than timolol (n ¼ 1)(P ¼ 0.01). Conclusions This study suggests that latanoprost provides a statistically lower 08:00-hour IOP and better range of IOP than timolol in the treatment of XFG glaucoma.

show abstract

The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma

Cited by 53 publications

References 22 publications

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma

Contact Info

Product

Resources

About